Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Update

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) was the target of a large growth in short interest in June. As of June 15th, there was short interest totaling 48,068 shares, a growth of 96.3% from the May 31st total of 24,488 shares. Currently, 1.7% of the shares of the stock are short sold. Based on an average trading volume of 29,463 shares, the days-to-cover ratio is currently 1.6 days.

Cyclerion Therapeutics Trading Up 1.8%

Shares of NASDAQ:CYCN opened at $3.43 on Friday. The firm has a market cap of $14.85 million, a price-to-earnings ratio of -2.52 and a beta of 1.74. The stock’s 50-day moving average price is $3.15 and its two-hundred day moving average price is $2.27. Cyclerion Therapeutics has a 12-month low of $1.03 and a 12-month high of $8.48.

Cyclerion Therapeutics (NASDAQ:CYCN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. As a group, research analysts forecast that Cyclerion Therapeutics will post -1.2 earnings per share for the current fiscal year.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. 75.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.